Увійти

Готові списки джерел за темами / Alfuzosine

Зміст

Статті в журналах
Дисертації
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "Alfuzosine"

Автор: Grafiati

Опубліковано: 28 жовтня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Alfuzosine".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Alfuzosine"

1

Marini, F., F. Martino, V. Alfano, G. P. Vancini, and R. Valente. "Trattamento Sintomatico Dell'Ipertrofia Prostatica Benigna Con Alfuzosine." Urologia Journal 57, no. 1 (February 1990): 29–34. http://dx.doi.org/10.1177/039156039005700105.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Guerre, A., D. M. Hartl, and P. Katz. "Les Alpha-1-Bloquants (alfuzosine) en pathologie salivaire obstructive." Revue de Stomatologie et de Chirurgie Maxillo-faciale 111, no. 3 (June 2010): 135–39. http://dx.doi.org/10.1016/j.stomax.2010.04.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

de Goede, A. "Alfuzosine geeft geen vermindering van symptomen van chronische prostatitis-chronische bekkenpijnsyndroom." Medisch-Farmaceutische Mededelingen 47, no. 4 (April 2009): 50–51. http://dx.doi.org/10.1007/bf03079915.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Carbin, B. E., P. Bauer, M. Friskand та D. Moyse. "EFFICACY OF ALFUZOSINE (an α₁-adrenoreceptor blocking drug) IN BENIGN HYPERPLASIA OF THE PROSTATE". Scandinavian Journal of Urology and Nephrology 25, sup138 (1 січня 1991): 73–75. http://dx.doi.org/10.1080/21681805.1991.12068870.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

El, Sheikh, Nahla Esmail, Ayman Gouda та Walid Basset. "Extractive spectrophotometric determination of some α-adrenergic-antagonists in pure forms and in pharmaceutical formulations". Chemical Industry and Chemical Engineering Quarterly 18, № 2 (2012): 179–91. http://dx.doi.org/10.2298/ciceq110917060e.

Повний текст джерела

Анотація:

A simple, rapid, and extractive spectrophotometric methods was developed for the determination of some postsynaptic ?-1 adrenoreceptor antagonist; doxazosin mesylate (DOX), terazosin (TRZ) and alfuzosine HCl (ALF) in pure forms and pharmaceutical formulations. The developed methods are based on the formation of yellow colored chloroform ion-pair complexes between the basic nitrogen of the drugs and dyes, namely; bromocresol green (BCG), bromothymol blue (BTB), methyl orange (MO) and alizarine red S (ARS), in acidic buffer of pH range (3.0-5.0). The formed complexes were extracted with chloroform or dichloromethane and measured at 418, 414, 425 and 426 nm for DOX and at 419, 415, 425 and 428 for TRZ and at 418, 412, 421 and 427 nm for ALF using BCG, BTB, MO and ARS, respectively. The analytical parameters and their effects on the reported systems are investigated. Beer?s law was obeyed in the range 1.0-130 ?g mL?1 with correlation coefficient (n = 6) ? 0.9991. The molar absorpitivity, Sandell sensitivity, detection and quantification limits were also calculated. The composition of the ion associates was found 1:1 by Job?s method. The proposed methods have been applied successfully for the analysis of the studied drugs in pure forms and in pharmaceutical formulations with percentage recoveries ranges from 99.18-100.61. The results of analysis were validated statistically. The results were in good agreement and compared with those obtained with reported methods.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Mari, Andrea, Alessandro Antonelli, Luca Cindolo, Ferdinando Fusco, Andrea Minervini, and Cosimo De Nunzio. "Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis." Therapeutic Advances in Urology 13 (January 2021): 175628722199328. http://dx.doi.org/10.1177/1756287221993283.

Повний текст джерела

Анотація:

Background: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are a bothersome frequent symptom in adult males. This systematic review analyzed the available evidence on the pharmacokinetic and pharmacodynamic features of alfuzosin, and its clinical efficacy both as monotherapy and in combination with other drugs for the treatment of male LUTS/BPH. Methods: A systematic review of the last 10 years was performed using the MEDLINE, EMBASE and Cochrane libraries in March 2020. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42020136120) and is available in full on the University of York website. Results: Alfuzosin is a quinazoline derivative and, although a nonspecific α1-blocker, exhibits a selective concentration in the prostate compared with plasma in patients with BPH. Three registration trials assessed the safety and efficacy of alfuzosin. The 10 mg daily formulation has a three-layered matrix containing the active substance between two inactive coats allowing a drug release over 20 h. Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. Six randomized clinical trials (RCTs) assessed efficacy and safety of alfuzosin versus other alpha-blockers ± placebo: three studies comparing with tamsulosin, one with doxazosin, and two with silodosin or tamsulosin. One RCT investigated the clinical outcomes of alfuzosin with finasteride, two with propiverine and two with phosphodiesterase-5 inhibitors. Conclusions: Alfuzosin is an effective drug for the treatment of LUTS/BPH, with a lower rate of sexual disorders compared with other alpha-blockers. Alfuzosin is also safe with low adverse events in case of concomitant antihypertensive therapy and in patients with cardiovascular morbidity. Safety and efficacy of alfuzosin has been reported also in case of combination therapy with antimuscarinic agents and PDE5i.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Siddique, Md Saifuddin Ahmed, Sharmin Nahar Bashar, Mohammed Monowar UL Haque, Md Abdul Latif, and Farid Uddin Ahmed. "Comparison Between Alfuzosin Monotherapy And Combination of Alfuzosin With Finasteride In Symptomatic Benign Prostatic Hyperplasia." Journal of Chittagong Medical College Teachers' Association 28, no. 2 (February 10, 2018): 75–80. http://dx.doi.org/10.3329/jcmcta.v28i2.62426.

Повний текст джерела

Анотація:

Background: Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are common in elder men and a number of drugs alone or combined are clinically used for this disorder. This study was aimed to evaluate the efficacy and safety of Alfuzosin monotherapy versus combination of Alfuzosin and Finasteride in treatment of LUTS due to BPH. Materials and methods: This clinical trial was conducted in the outpatient Department of Urology Chittagong Medical College Hospital from May 2007 to October 2008. After assessing for the eligibility, consecutive consenting 60 patients with LUTS related to BPH were randomly assigned to either 10mg Alfuzosin (Group A) or combination of 10mg Alfuzosin and 5mg Finasteride (Group B) for 12 months. The response was assessed by measurements of International Prostate Symptoms Score (IPSS) Maximum urine flow rate (Qmax), Post Voidal Residual Volume (PVR) and prostate volume at baseline and 3 monthly thereafter. Safety was assessed by Adverse Drug Events (ADE) rate. Results: Both Groups showed comparable significant improvements in all parameters in terms of decreasing IPSS, PVR and increasing Qmax. Both treatments were well tolerated with respect to ADE and distribution of ADE was similar in two groups. Conclusion: In men with benign prostatic hyperplasia, Alfuzosin was effective therapy and the combination of Alfuzosin and Finasteride was no more effective than Alfuzosin alone. JCMCTA 2017 ; 28 (2) : 75-80

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Vamsi Krishna, M., and D. Gowri Sankar. "Optimization and Validation of Quantitative Spectrophotometric Methods for the Determination of Alfuzosin in Pharmaceutical Formulations." E-Journal of Chemistry 4, no. 3 (2007): 397–407. http://dx.doi.org/10.1155/2007/912762.

Повний текст джерела

Анотація:

Three accurate, simple and precise spectrophotometric methods for the determination of alfuzosin hydrochloride in bulk drugs and tablets are developed. The first method is based on the reaction of alfuzosin with ninhydrin reagent inN, N'-dimethylformamide medium (DMF) producing a colored product which absorbs maximally at 575 nm. Beer’s law is obeyed in the concentration range 12.5-62.5 µg/mL of alfuzosin. The second method is based on the reaction of drug with ascorbic acid in DMF medium resulting in the formation of a colored product, which absorbs maximally at 530 nm. Beer’s law is obeyed in the concentration 10-50 µg/mL of alfuzosin. The third method is based on the reaction of alfuzosin withp-benzoquinone (PBQ) to form a colored product with λmax at 400 nm. The products of the reaction were stable for 2 h at room temperature. The optimum experimental parameters for the reactions have been studied. The validity of the described procedures was assessed. Statistical analysis of the results has been carried out revealing high accuracy and good precision. The proposed methods could be used for the determination of alfuzosin in pharmaceutical formulations. The procedures were rapid, simple and suitable for quality control application.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Shrestha, Santosh, DB Adhikari, A. Gurung, S. Pradhan, NV Gurung, A. Acharya, D. Shrestha, et al. "Role of Alfuzosin in Ureteral Stent Related Urinary Symptoms Score: A Comparative Study." Journal of Gandaki Medical College-Nepal 10, no. 1 (August 1, 2017): 28–30. http://dx.doi.org/10.3126/jgmcn.v10i1.17912.

Повний текст джерела

Анотація:

Background: Ureteral stent placement is a routine urological procedure. However, patients inserted with ureteral stent exhibited increased urinary symptoms that compromise patients’ quality of life.Objective: To assess the efficacy of alpha blockers (Alfuzosin) in the management of ureteral stent related urinary symptoms.Methods: Total of 60 patients after ureteral stent insertion was randomly divided into two equal groups; 30 in alfuzosin group and the remaining 30 in control group. Urinary symptoms questionnaire was filled after two weeks and results were statistically analyzed.Results: Urinary symptoms like urgency, frequency and flank pain were significantly less in the alfuzosin group when compared with control group.Conclusion: Alpha blocker (Alfuzosin) was found to be effective in reducing ureteral stent related urinary symptoms.Journal of Gandaki Medical CollegeVol. 10, No. 1, 2017, page: 28-30

Стилі APA, Harvard, Vancouver, ISO та ін.

10

&NA;. "Alfuzosin." Reactions Weekly &NA;, no. 729 (November 1998): 6. http://dx.doi.org/10.2165/00128415-199807290-00015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Alfuzosine"

1

Ah-hot, Michel. "Effest de l'alfuzosine par voie intraveineuse sur l'hémodynamique de l'insuffisant cardiaque." Paris 5, Cochin, 1988. http://www.theses.fr/1988PA05C031.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Liu, Quan. "Development of a novel gastro-retentive delivery system using alfuzosin HCl as a model drug." Diss., Temple University Libraries, 2010. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/80170.

Повний текст джерела

Анотація:

Pharmaceutics;
Ph.D.
The objectives of this project encompass the design and development of a drug delivery system to continuously deliver therapeutic agents from the stomach to the proximal region of the intestine. The delivery system designed would have sufficient gastric residence time together with near zero-order release kinetics. The physicochemical properties pertaining to the formulation development of the model drug (alfuzosin HCl) were evaluated. Excipients were selected based on the studies of their physicochemical properties and compatibility with the active ingredient. Gastro-retentive dosage forms have been the topic of interest in recent years as a practical approach in drug deliveries to the upper GI tract or for release prolongation and absorption. These dosage forms are particularly suitable for drugs that have local effects on the gastric mucosa in the stomach. Other candidates include drugs that are likely to be absorbed in the upper small intestine, or drugs that are unstable in basic environment of distal intestine and colon or those with low solubility at elevated pH conditions (i.e. weak bases). To develop a gastro-retentive delivery system the following steps were taken. First, to investigate the possible incompatibility issues between the model drug and excipients to be used for the delivery system. Stability and physicochemical properties of the active agent and its mixture with excipients were studied using analytical techniques such as Raman spectroscopy and Differential scanning calorimetry (DSC). No incompatibility issues were detected. Second, Kollidon SR as a relatively new release-rate controlling polymer was incorporated in the final formulation. For solid dosage form the ability of the final powder mix to flow well during manufacturing and the intrinsic characteristics that make it compressible are critical. The in-depth compaction study of Kollidon SR was assessed with the help of a compaction simulator. The flowability, swelling and erosion behavior together with release-rate retarding properties of Kollidon SR were also assessed. The final oral delivery system was based on Kollidon SR and Polyethylene Oxide (PEO) 303 as a monolithic matrix system. The noneffervescent monolithic matrix was made by direct compression. In vitro evaluation of the designed system released the active content in a near zero manner. The dosage form was bouyant in pH 2.0 acidic buffer with no floatation lag time which minimizes the possibility of early gastric emptying.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Lee, Wei-Yang, and 李維揚. "Preparation and release studies of alfuzosin matrix and matrix-coating system." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/3mhp48.

Повний текст джерела

Анотація:

碩士
嘉南藥理科技大學
藥物科技研究所
97
Three common oral controlled delivery systems including matrix, reservoir, and osmotic pump system are often used in the pharmaceutical field. The aim of this study is to investigate the performance and mechanism of different formulations of alfuzosin hydrochloride using matrix and matrix-coating system. Different excipients such as water swellable polymeric matrices have found broad application in controlled release system, and diffusion often controls the rate of drug release from the system. Therefore, in order to control drug release, characterization of the effects of the polymer blends and polymer swelling on drug release diffusion is crucial. In the present study, direct compression method was utilized to prepare matrix tablets. The amounts of hydroxyl propyl methyl cellulose (HPMC) in matrix and various amount of hydrophilic / hydrophobic polymers in matrix -coating membrane were studied to assess drug release characteristics. The coating membrane used were percentage of 3% and 5%. Drug permeability and mechanical properties of polymer membrane with different composition were determined. Dissolution tests were performed according to the USP paddle method (900 ml medium, 37 ± 0.5℃ and 100 rpm). For matrix tablets, the results indicate that drug release rates can be decreased by increasing amount of HPMC. Swelling results are also consistent with drug release results. Higher swelling and less erosion were observed for tablet with higher amount of HPMC. For matrix-coating systems, the results indicate that drug release rates can be decreased by increasing amount of hydrophobic polymers in polymer blend and coating percentage. The results demonstrate that controlled release of alfuzosin hydrochloride is feasible using matrix and matrix-coating system.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Chang, Shu-chen, and 張素真. "Evaluation of the combined use of saw palmetto and alfuzosin in the treatment of benign prostatic hyperplasia." Thesis, 2006. http://ndltd.ncl.edu.tw/handle/29rynz.

Повний текст джерела

Анотація:

碩士
南華大學
自然醫學研究所
95
This study aims to investigate the clinical effects of a phytotherapeutic agent saw palmetto, the drug Alfuzosin, both singly and jointly in patients experiencing lower urinary tract symptoms (LUTS) who were also diagnosed with benign prostatic hyperplasia (BPH). A total of 28 patients diagnosed with BPH and met the study criteria were divided into three groups based on the severity of their symptoms. Those of mild severity (n=10) were asked to take saw palmetto extract at 320mg per day (Group P) and those of moderate severity (n=10) were asked to take alfuzosin at 10 mg per day (Group A). Those of greatest severity (n=8) were asked to take both saw palmetto extract and alfuzosin (Group PA). Serum prostate specific antigen (PSA), maximal flow rate (Qmax), prostate volume (PV), and the International Prostate Symptom Score (IPSS) were obtained at the baseline and at the end of the three-month intervention. Results indicated that PV decreased by 4.8±8.2cc and 3.8±1.8cc in the Group P and Group PA and the reduction was significantly lowered than that in the Group A (p=0.032). 　　　In the IPSS score, the reduction in Group PA (-7.6±3.0) and Group A (-4.3±1.3) were significantly greater than that of Group P (-3.1±3.0) (p=0.003). The reduction in score was attributed by the changes in the obstructive symptoms (p=0.005) and three of its four items, namely, incomplete emptying (p=0.029), intermittency (p=0.032), and weak stream (p=0.018). The reduction in Group P was not significantly differed from that of Group A and that Group PA was not significantly differed from that of Group A. In conclusion, this study found that saw palmetto extract can improve certain lower urinary tract symptoms, particularly those of obstruction in nature, associated with BPH. 　　　The combined effect of saw palmetto and alfuzosin appeared to be more significant than when these agents were used singly. Future clinical studies in this area may provide patients with BPH additional therapeutical choices.

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Alfuzosine"

1

Zwaveling, J. "Waarom moet tamsulosine tijdens het ontbijt en waarom alfuzosine tijdens het avondeten worden ingenomen?" In Vademecum permanente nascholing huisartsen, 3332–33. Houten: Bohn Stafleu van Loghum, 2006. http://dx.doi.org/10.1007/978-90-313-8808-0_1738.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

"Alfuzosin." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 74–75. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00400-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

"ALFUZOSIN." In Litt's Drug Eruptions and Reactions Manual, 24. CRC Press, 2014. http://dx.doi.org/10.1201/b15347-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

"Alfuzosin." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-43.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Michel, Martin C. "Alfuzosin." In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.63088-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

"Alfuzosin." In Meyler's Side Effects of Drugs, 142–43. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.00244-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

"Alfuzosin." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Stuttgart: Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82206.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

"Alfuzosin." In Hale’s Medications & Mothers’ Milk™ 2019. New York, NY: Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0023.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

"Alfuzosin A Jardin." In Therapeutic Treatment for Benign Prostatic Hyperplasia, 127–46. CRC Press, 2005. http://dx.doi.org/10.1201/b14479-11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Mahapatra, Abikesh Prasada Kumar, Sonia P. Nagvenkar, and Rajashree Gude. "Studying Formulation and Physicochemical Characterization of Buccal Mucoadhesive Films Containing Alfuzosin Hydrochloride." In Technological Innovation in Pharmaceutical Research Vol. 1, 75–88. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/tipr/v1/2271e.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Alfuzosine"

1

Mamina, O., V. Kabachny, and N. Bondarenko. "ANALYSIS OF ALFUZOSIN BY HPLC METHOD." In DÉBATS SCIENTIFIQUES ET ORIENTATIONS PROSPECTIVES DU DÉVELOPPEMENT SCIENTIFIQUE. European Scientific Platform, 2021. http://dx.doi.org/10.36074/logos-05.02.2021.v6.29.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Philip, C., and A. Glanard. "DI-067 Retrospective study of alfuzosin 10 mg prescriptions." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.314.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Churakov, A. A. "КОМБИНИРОВАННАЯ ЭРИКСОНОВСКАЯ ПСИХОТЕРАПИЯ В КОМПЛЕКСНОМ ЛЕЧЕНИИ КОМОРБИДНОГО ПАЦИЕНТА". У ПЕРВЫЙ МЕЖКОНТИНЕНТАЛЬНЫЙ ЭКСТЕРРИТОРИАЛЬНЫЙ КОНГРЕСС «ПЛАНЕТА ПСИХОТЕРАПИИ 2022: ДЕТИ. СЕМЬЯ. ОБЩЕСТВО. БУДУЩЕЕ». Crossref, 2022. http://dx.doi.org/10.54775/ppl.2022.78.49.001.

Повний текст джерела

Анотація:

Patient «C», 51 years old, works as an oncologist in a hospital, mostly night duties. Complaints of anxiety; reduced mood; hopelessness, “all is bad: health, work, family”; guilt; weakness; apathy, suicidal thoughts; sleep disturbance; chronic back pain; feeling of incomplete bladder emptying. He associates the complaints with high stress at work and with the fact that he does not have time to recover from night duty, with a sense of hopelessness due to his inability to help some patients. He was observed by an interdisciplinary team of specialists including a psychotherapist, a urologist and a neurologist. Diagnosis: Emotional burnout syndrome (Z 73.0), Mixed anxiety and depressive reaction (F 43.22), Neurogenic bladder weakness (N 31.2), Dorsopathy at lumbarsacral level (М 51.1). Prescription: alfuzosin (alfuprost, Vertex, Russia) 10 mg per 24 hours, 3 months; tolperison hydrochloride (mydocalm, GEDEON RICHTER, Plc., Hungary), per os 150 mg in the evening, for 1 month; psychotherapy in Erickson's hypnosis modality: 2 in-person sessions – “Resource Vase” and “Compassion meditation”, and 10 sessions of neuro audio modules (NAM): Psychosomatic Session, Good Memory, House Building, Bird Flight, Body Comfort Bird, Health Bridge, Diaphragmatic Breathing, Transformation, Garden, Circulation of Transformations, River of Desire, they were held daily or every other day. NAM was broadcast against the background of meditative music and sounds of nature. Methods of self-regulation of psycho-emotional state are recommended. One month later after the beginning of the treatment: the level of anxiety decreased from 16 till 6 points, the level of depression – from 12 till 5 points (HADS). Back pains dimineshed from 8 till 3 points according to Visual Analog scale, 55% residual urine. The patient noted a significant improvement in the background mood, a surge of energy, increased working capacity, improvement in the relations with his loved ones. Thus, the clinical effectiveness of inclusion in the treatment of comorbid patient of combined Erickson's psychotherapy with the predominant use of NAM has been demonstrated. This approach increases the availability of psychotherapy, reduces labour efforts of a therapist and financial burden on a patient. Пациент «C», 51 г., работает врачом-онкологом в стационаре, преимущественно ночные дежурства. Обратился с жалобами: чувство тревоги; пониженный фон настроения; ощущение безнадежности, «все плохо: здоровье, работа, семья»; чувство вины; упадок сил; апатия, суицидальные мысли; нарушение ночного сна; хроническая боль в спине; чувство неполного опорожнения мочевого пузыря. Жалобы связывает с выраженным стрессом на работе и тем, что не успевает восстанавливаться после ночных дежурств, ощущением безысходности из-за невозможности помочь некоторым пациентам. Наблюдался междисциплинарной командой специалистов, включающей психотерапевта, уролога, невролога. Диагноз: Синдром эмоционального выгорания (Z 73.0), Смешанная тревожная и депрессивная реакция (F 43.22), Нейрогенная слабость мочевого пузыря (N 31.2), Дорсопатия на пояснично-крестцовом уровне (М 51.1). Назначения: алфузозин (алфупрост, Вертекс, Россия) 10 мг в сутки, 3 месяца; толперизона гидрохлорид (мидокалм, GEDEON RICHTER, Plc., Венгрия), внутрь 150 мг вечером, 1 месяц; психотерапия в модальности Эриксоновский гипноз: 2 сеанса очно – «Ваза 163 ресурсов» и «Медитация сострадания», и 10 сеансов нейроаудиомодулей (НАМ): Психосоматический сеанс, Приятное воспоминание, Строительство дома, Полет птицы, Птица телесного комфорта, Оздоровительный мост, Диафрагмальное дыхание, Трансформация, Сад, Круговорот преобразований, Река желания, которые проводили ежедневно или через день. НАМ транслировался на фоне медитативной музыки и звуков природы. Рекомендованы приемы саморегуляции психоэмоционального состояния. Через 1 месяц от начала лечения: уровень тревоги снизился с 16 до 6 баллов, депрессии – с 12 до 5 баллов (ГШТД). Уменьшились боль в спине по ВАШ с 8 до 3 баллов, объем остаточной мочи на 55%. Пациент отметил значительное улучшение фона настроения, прилив сил, повысилась работоспособность, улучшились отношения с близкими. Таким образом, продемонстрирована клиническая эффективность включения в курс лечения коморбидного пациента комбинированной эриксоновской психотерапии с преимущественным использованием НАМ. Данный подход повышает доступность к психотерапии, сокращает трудозатраты врача-психотерапевта и финансовую нагрузку на пациента.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!